Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing products to primary care, orthopedic surgeons and rheumatologists. The Company markets DUEXIS®, RAYOS®/LODOTRA® and VIMOVO® , which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians while taking advantage of its commercial strengths and the infrastructure the Company has put in place.
Bob De Vaere
Chief Financial Officer
Horizon Pharma, Inc.
520 Lake Cook Road, Suite 520
Deerfield, IL 60015
E. Blair Clark-Schoeb
View all Recent Releases
Horizon Pharma Announces Stockholder Approval of Its Acquisition of Vidara Therapeutics International plc and Expected Transaction Closing on September 19th
DEERFIELD, IL -- (Marketwired) -- 09/18/14 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that at its Special Meeting of Stockholders held today, proposals related to Horizon's acquisition of Vidara Therapeutics International plc were approved by Horizon's stockholders.
As previously announced, on March 18, 2014, Horizon Pharma, Inc. ("Horizon"), Vidara Therapeutics Holdings LLC, Vidara Therapeutics International plc, an Irish public limited company ("Vidara"), Hamilton Holdings (USA), Inc., an indirect wholly-owned subsidiary of Vidara ("U.S. HoldCo"), and Hamilton Mer...
Read more »
Horizon Pharma to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014
DEERFIELD, IL -- (Marketwired) -- 09/02/14 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, chairman, president and chief executive officer, will present in a fireside chat format discussion at the Morgan Stanley Global Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at 8:45 a.m. Eastern Time in New York, NY. Mr. Walbert will provide an overview of the Company and its corporate activities.
The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webca...
Read more »
Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS® (Prednisone) Delayed-Release Tablets
DEERFIELD, IL -- (Marketwired) -- 08/27/14 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the United States Patent and Trademark Office (USPTO) has issued Horizon a Notice of Allowance for U.S. patent application number 13/860,015 entitled "Delayed-Release Glucocorticoid Treatment of Rheumatoid Disease" that covers Horizon's U.S. approved product RAYOS® (prednisone) delayed release tablets.
"This patent allowance by the USPTO is not only another important milestone in protecting the commercial potential of RAYOS, but along with other recent allowances, demonst...
Read more »
Horizon Pharma Announces U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen / esomeprazole) Delayed Release Tablets
DEERFIELD, IL -- (Marketwired) -- 08/13/14 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that POZEN Inc. (NASDAQ: POZN), has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/045,156 entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that covers Horizon and POZEN'S U.S. approved product VIMOVO® (naproxen / esomeprazole magnesium) delayed release tablets.
"The claims included in this Notice of Allowance continue to expand the strength of the VIMOVO patent estat...
Read more »
Horizon Pharma Announces Effectiveness of S-4 Registration Statement for Acquisition of Vidara Therapeutics International Public Company Limited
DEERFIELD, IL -- (Marketwired) -- 08/08/14 --
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the S-4 registration statement filed by Vidara Therapeutics International Public Limited Company ("Vidara") with the Securities and Exchange Commission on June 26, 2014, as amended on July 28, 2014 and August 6, 2014 regarding the proposed acquisition of Vidara through a reverse merger with Horizon Pharma was declared effective by the SEC on August 7, 2014.
The Company also announced that Horizon has scheduled a special meeting of its stockholders on Thursday, September 18, 2...
Read more »